An interventional study of Simulated indoor thermal environment in Chronic Obstructive Pulmonary Disease (COPD) and Heat Stress, sponsored by University of Ottawa. Not yet recruiting at 1 site in Canada. Open to participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by University of Ottawa · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 398 studies in Pulmonary Disease, Chronic Obstructive with a site in Canada — 40 open to participants now, 49 under way, 9 of them phase 3. Pulmonary Disease, Chronic Obstructive · Canada.
Among the 398 studies in Pulmonary Disease, Chronic Obstructive with a site in Canada, this one is the 305th largest by planned enrollment of the 340 interventional ones that give a count, is one of 9 that started in 2026, is one of 120 with no phase, reaches primary completion later than 22 of the 48 other live ones, and was the 397th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →40 of the 398 studies in Pulmonary Disease, Chronic Obstructive with a site in Canada are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Canada, United States, Argentina and 15 more countries
Ages 40–75
Expedition Therapeutics, Inc · Sites in Canada, United States, Georgia and 1 more country
Ages 40–85
University of British Columbia · Sites in Canada
Ages 19–80 · Healthy volunteers
Western University, Canada · Sites in Canada
Ages 50–85
Pfizer · Sites in Canada, United States, Argentina and 15 more countries
Ages 35–80
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 60 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
398 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 59 · Phase 3 122 · Phase 4 42
First in 2000; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 18 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 207 across the 340 interventional studies, 115 across the 57 observational. Of the 313 that completed or were terminated, 133 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
184 of 398 have an industry lead sponsor. The 10 most frequent:
University of Ottawa is the lead sponsor of 125 studies on the registry; 31 are open to participants now.
University of Ottawa has 1 study filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
12 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT05543720University Health Network, TorontoEvaluation of Nurse-led Integrated Care of Complex Patients Facilitated By Telemonitoring: The SMaRT Study | 2026-12 |
| NCT06712563AstraZenecaPooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting | 2026-12-14 |
| NCT06969573University of AlbertaInhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD | 2026-12-31 |
| NCT06825013Dr. J. Alberto NederBronchodilators and Lung Mechanics During Exercise in COPD | 2027-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 398 studies in Pulmonary Disease, Chronic Obstructive with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
During warm weather, homes without air conditioning can stay hot for long periods, and most heat-related health problems in Canada happen indoors rather than outdoors. Health Canada recommends that indoor temperatures not exceed 26 °C in homes occupied by people who are more susceptible to heat. That recommendation is based largely on population-level evidence, and very little is known about how susceptible individuals actually respond, physiologically, when indoor temperatures rise above it.
Older adults living with chronic obstructive pulmonary disease (COPD) are among the groups identified as more susceptible to heat. COPD involves persistent airflow limitation, reduced lung and cardiovascular reserve, and altered cellular stress responses. Despite this, no laboratory study has directly measured how adults with COPD respond to a full day spent indoors in warm conditions.
This randomized crossover trial will measure how older adults with COPD respond to two different indoor environments, each experienced for eight hours on separate days at least one week apart. One day is spent at the recommended indoor temperature limit and the other at a warmer temperature representative of conditions recorded inside Canadian homes during hot weather. Participants remain seated and rest throughout; no exercise or work is performed.
Throughout each day, the research team continuously measures core body temperature, skin temperature, heart rate, and measures blood pressure, lung function, breathlessness, thermal comfort, cognitive performance, and balance at set time points. Blood and urine samples are collected at the start and end of each day. Participants are monitored continuously by trained staff.
The results are intended to strengthen the evidence base behind Canadian indoor temperature guidance and to inform recommendations for protecting people living with chronic lung disease during hot weather.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eight-hour passive seated exposure to an indoor environment maintained at 26 °C and 45% relative humidity, corresponding to the recommended upper indoor temperature limit for heat-susceptible occupants.
Other: Simulated indoor thermal environment
Eight-hour passive seated exposure to an indoor environment maintained at 36 °C and 45% relative humidity, representing warm indoor conditions recorded inside Canadian dwellings without mechanical cooling during heat events.
Other: Simulated indoor thermal environment
Day-long (8 h) passive exposure in a climate-controlled environmental chamber at a set air temperature and relative humidity. Participants remain seated or resting.
Core temperature (Peak)
Peak rectal temperature (15 min average) during exposure. Rectal temperature is measured continuously throughout the simulated indoor overheating exposure.
Time frame: End of 8-hour exposure
Profiles of Mood States (POMS)
Potential changes in mood (7 subscales of mood: tension, anger, depression, fatigue, confusion, vigor and esteem-related affect). The POMS-40 is a validated, self-administered questionnaire that examines seven distinct aspects of mood state across two positive subscales (Esteem-Related Affect, and Vigor) and five negative subscales (Fatigue, Tension, Confusion, Anger, and Depression), which are described across 40 distinct adjectives. For each individual item, participants were asked to describe "how you feel right now" by responding using a 5-point Likert scale (0 = "Not at all", 1 = "A little", 2 = "Moderately", 3 = "Quite a lot", or 4 = "Extremely"). The values of items associated with a specific subscale (e.g., Fatigue) were summed to calculate its score.
Time frame: At the start (hour 0) and end of exposure (hour 8)
Environmental Symptoms Questionnaire (ESQ)
Self-reported environmental reactions and medical symptomatology associated with prolonged heat exposure. The ESQ-IV is a validated 68-item, self-administered questionnaire that has been used successfully in identifying symptomatology during exposure to a wide variety of environmental conditions, including heat exposure \[24, 25\]. Participants are asked to assess and described "how you have been feeling today" by responding to each item using a 6-point Likert scale (0 = "Not at all", 1 = "Slight", 2 = "Somewhat", 3 = "Moderate", 4 = "Quite a bit", or 5 = "Extreme"). Total Symptom Score was calculated from this data by taking the sum of the intensity ratings from all 68 individual items using reverse scores for the three positive items from the list ("I Felt Good", "I Felt Alert", and "I Felt Wide Awake").
Time frame: At the start (hour 0) and end of exposure (hour 8)
Orthostatic intolerance symptoms assessment
Cumulative sum of scores on 6 questions asking participant to rank symptoms associated with orthostatic intolerance during the lying to standing tests. All symptoms scored on a scale from 0 (none) to 10 (worst possible) and include feelings of: (1) "dizziness, lightheadedness, feeling faint, or feeling like you might black out"; (2) "Problems with vision (blurring, seeing spots, tunnel vision, etc.)"; (3) "Weakness"; (4) "Fatigue"; (5) "Trouble concentrating"; and (6) "Head and neck discomfort".
Time frame: At the start (hour 0) and end of exposure (hour 8)
Perceived arousal (Felt Arousal Scale)
Perceived arousal assessed using the Felt Arousal Scale, a single-item 6-point numerical rating scale on which participants respond to the question "How worked up are you?" Scores range from a minimum of 1 (low arousal) to a maximum of 6 (high arousal).
Time frame: End of 8-hour exposure
Perceived thirst (Thirst Sensation Scale)
Perceived thirst assessed using the Thirst Sensation Scale, a single-item 9-point numerical rating scale on which participants respond to the question "How thirsty do you feel now?" Scores range from a minimum of 1 to a maximum of 9, with verbal anchors at 1 (not thirsty at all), 3 (a little thirsty), 5 (moderately thirsty), 7 (very thirsty), and 9 (very, very thirsty).
Time frame: End of 8-hour exposure
Thermal sensation (American Society of Heating, Refrigerating and Air-Conditioning Engineers thermal sensation scale)
Thermal sensation assessed using the thermal sensation scale defined in ANSI/ASHRAE Standard 55 (American Society of Heating, Refrigerating and Air-Conditioning Engineers), a single-item 7-point bipolar rating scale on which participants respond to the question "How do you feel right now?" Scores range from a minimum of -3 (cold) to a maximum of +3 (hot), with 0 indicating a neutral thermal sensation.
Time frame: End of 8-hour exposure
Thermal comfort (American Society of Heating, Refrigerating and Air-Conditioning Engineers thermal comfort scale)
Thermal comfort assessed using the thermal comfort scale defined in ANSI/ASHRAE Standard 55 (American Society of Heating, Refrigerating and Air-Conditioning Engineers), a single-item 4-point rating scale on which participants respond to the question "How comfortable do you feel right now?" Scores range from a minimum of 1 (comfortable) to a maximum of 4 (very uncomfortable).
Time frame: End of 8-hour exposure
Change in plasma volume
Change in plasma volume from baseline values calculated from duplicate measurements of hemoglobin and hematocrit at the start and end of each exposure using the technique by Dill and Costill
Time frame: End of 8-hour exposure
Fluid loss
Fluid loss calculated as the change in body mass during each exposure presented as a percentage of baseline body mass (corrected for food consumption)
Time frame: End of 8-hour exposure
Fluid consumption
Average hourly fluid consumption calculated by weighing participant water intake at the start and end of each hour of exposure (normalized to the exposure duration).
Time frame: End of 8-hour exposure
Heart rate variability: RMSSD
Root mean squared standard deviation of normal-to-normal R-wave to R-wave intervals (RMSSD) measured during 5 minutes of paced breathing (15 breaths/min) with participants in the seated position. RMSSD will be evaluated twice, during two paced breathing periods (separated by 4 min of seated rest).
Time frame: At the start (hour 0) and end of exposure (hour 8)
Heart rate variability: SDNN
Standard deviation of normal-to-normal R-wave to R-wave intervals (SDNN) measured during 5 minutes of paced breathing (15 breaths/min) with participants in the seated position. SDNN will be evaluated twice, during two paced breathing periods (separated by 4 min of seated rest).
Time frame: At the start (hour 0) and end of exposure (hour 8)
Rate pressure product
Rate pressure product, an index of myocardial work and strain, calculated as systolic blood pressure x heart rate.
Time frame: End of 8-hour exposure
Diastolic blood pressure
Diastolic blood pressure measured in triplicate via automated oscillometry (\~60 seconds between measures)
Time frame: End of 8-hour exposure
Systolic blood pressure
Systolic blood pressure measured in triplicate via automated oscillometry (\~60 seconds between measures)
Time frame: End of 8-hour exposure
Systolic Response to Standing From Supine
Systolic blood pressure response to standing evaluated as the difference in blood pressure measured between the standing and supine. Standing systolic blood pressure will be taken as the lowest value of those measured after 60 and 120 seconds of standing. Systolic response to standing will be evaluated twice, during two lying-to-standing tests (separated by 10 min of supine rest).
Time frame: At the start (hour 0) and end of exposure (hour 8)
CDC 4-Stage Balance Test (Postural stability)
To assess postural stability, participants hold a tablet to their chest, then auditory cues guide participants through four consecutive stances, feet side by side, instep of one foot touching the big toe of the other foot, tandem stand with one foot in front of the other, heel touching toe, and stand on one foot. The balance assessment will be evaluated based on movement detected by an accelerometer integrated into the hardware of the tablet device (Sway Medical Inc).
Time frame: At the start (hour 0) and end of exposure (hour 8)
Executive function (cognitive function)
Participants will be provided with a tablet device with the Sway Medical testing platform for the assessment of executive function. Participants will complete the Cued Stroop test, in which they are presented a sequence of congruent, neutral and incongruent colour-word tasks.
Time frame: At the start (hour 0) and end of exposure (hour 8)
Memory recall (cognitive function)
Participants will be provided with a tablet device with the Sway Medical testing platform for the assessment of memory recall. Participants complete both a delayed recall test and a working memory test.
Time frame: At the start (hour 0) and end of exposure (hour 8)
Impulse control (cognitive function)
Participants will be provided with a tablet device with the Sway Medical testing platform for the assessment of impulse control. Participants will be asked to respond to both "go" and "no-go" visual cues. In response to the "go" cue, participants will initiate a movement of the device.
Time frame: At the start (hour 0) and end of exposure (hour 8)
Reaction time (cognitive function)
Participants will be provided with a tablet device with the Sway Medical testing platform for the assessment of reaction time. Participants will be asked to initiate a movement of the device in response to a visual cue.
Time frame: At the start (hour 0) and end of exposure (hour 8)
Cardiac response to standing from supine (30:15 Ratio)
Cardiac response to standing evaluated as the ratio between the highest R-wave to R-wave interval (lowest heart rate) measured at the 30th heart beat after standing from supine (+/- 5 beats) and the lowest R-wave to R-wave interval (highest heart rate) measured at the 15th heart beat after standing (+/- 5 beats). Cardiac response to standing will be evaluated twice, during two lying-to-standing tests (separated by 10 min of supine rest). Assessment is performed in the morning prior to and following daytime exposure.
Time frame: At the start (hour 0) and end of exposure (hour 8)
Heart rate (AUC)
Area under the curve of heart rate (in bpm-hours)
Time frame: End of 8-hour exposure
Heart rate (Peak)
Peak Heart rate (15-min average) during the 8-hour exposure
Time frame: End of 8-hour exposure
Core temperature (AUC)
Area under the curve of rectal temperature (in degree-hours)
Time frame: End of 8-hour exposure
Core temperature (hourly)
Rectal temperature measured at each hour of exposure (15-min average)
Time frame: Hourly during the 8-hour exposure
Mean skin temperature (Peak)
Peak mean skin temperature (15-min average) during the 8-hour exposure
Time frame: End of 8-hour exposure
Mean skin temperature (AUC)
Area under the curve of mean skin temperature (in degree-hours)
Time frame: End of 8-hour exposure
Urine specific gravity
Urine specific gravity measured by handheld refractometer
Time frame: At the start (hour 0) and end of exposure (hour 8)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for May 2027, 7 months later.
Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 7 months is below that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →